^
Association details:
Biomarker:ERCC1 N118N
Cancer:Osteosarcoma
Drug:cisplatin (DNA synthesis inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

Excerpt:
Eight single nucleotide polymorphisms in ERCC2, XPC, XPA, ERCC1, ERCC4 and ERCC5 genes were analyzed in 91 patients diagnosed with osteosarcoma and treated with cisplatin….We only observed a tendency towards an increased risk of poor tumor response and reduced EFS in patients carriers of the polymorphic alleles for ERCC1 Lys504Gln and ERCC1 Asn118Asn polymorphisms.
DOI:
10.1038/tpj.2009.19